Community-acquired common infections are where the most “Biocreep” has occurred. Therefore a small delta is appropriate and the best comparative agent should be selected.

Intravenous therapy for serious infections are the main problem in clinical development where physicians will select the best therapy. The delta should be based on statistical and clinical considerations and comparative therapy should represent the standard of care.